News and Events
DR. GENDELMAN HONORED FOR HUMANITARIAN WORK
Howard Gendelman, M.D., professor and chair of the UNMC Department of Pharmacology and Experimental Neuroscience, received the Humanitarian of the Year Award from the Jewish Federation of Omaha at a ceremony on June 5. Read a story on Dr. Gendelman from the Jewish Press.
REMEMBERING: MIKE BOSKA, PH.D.
Mike Boska, Ph.D., whose expertise in magnetic resonance imaging research benefited countless scientists at UNMC, died Saturday (May 13) in a one-man glider accident near the Blair, Neb., airport. He was 59.
Read more ...
UNMC SCIENTISTS ACHIEVE RESEARCH MILESTONE WITH PARKINSON'S DISEASE
In an early phase human clinical trial, researchers at UNMC tested a drug that transforms the immune system for diagnostic and therapeutic gain in Parkinson's disease (PD).
THREE UNMC STUDENTS NAMED PURDUE PHARMA SCHOLARS
UNMC Graduate Studies has announced its first cohort of Purdue Pharma Scholars, a program that provides funding for UNMC graduate students conducting neuroscience, pharmaceutical science or pain research. The annual scholarships are just one aspect of larger, ongoing partnership between UNMC and Purdue Pharma L.P.
NOVEL PHARMACEUTIC ACTION FOR HIV/AIDS DISCOVERED
A research team at UNMC has used a process they call LASER ART (long-acting slow effective release antiretroviral therapy) to discover an unexpected pathway to open cell storage areas for antiviral drugs. The discovery could revolutionize current treatments for HIV/AIDS by extending the actions of disease-combating medicines.
DR. LYUBCHENKO NAMED TO THE EDUCATION BOARD AT THE AMERICAN HEALTH COUNCIL
Yuri Lyubchenko, Ph.D., professor, pharmaceutical science, College of Pharmacy, has been named to the Education Board at the American Health Council. A UNMC Distinguished Scientist in 2008, Dr. Lyubchenko has been at UNMC since 2004. His areas of expertise include nanomedicine, biophysics and nanotechnology. He has had 254 articles published in peer-reviewed publications. The American Health Council is comprised of medical leaders and innovators and includes practitioners in allied health, dentistry, obstetrics, medicine, nursing, optometry, pharmacy, psychology and other health professions. The goal of the council is to maintain and improve the physical and mental health of Americans.
MEET DISTINGUISHED SCIENTIST LARISA POLUEKTOVA, M.D., PH.D.
This profile is part of a series to highlight the researchers who will be honored at a ceremony for UNMC's 2016 Scientist Laureate, Research Leadership, Distinguished Scientist and New Investigator Award recipients.
The Distinguished Scientist Award -- which is sponsored by the chancellor -- recognizes researchers who have been among the most productive scientists in the country during the past five years.
UNMC is part of a seven-university consortium working on a three-year, $8.6 million grant from the National Institutes of Health to map the heart's nervous system. The group's goal -- to conduct research that leads to new ways to treat cardiovascular disease by targeting nerves in the heart. Irving Zucker, Ph.D., professor and chair of the UNMC Department of Cellular and Integrative Physiology, is the principal investigator for the UNMC component.
DR. VETRO NAMED COP'S DISTINGUISHED TEACHER OF 2016
Joseph Vetro, Ph.D., assistant professor of pharmaceutical sciences, was named Distinguished Teacher of the Year at the College of Pharmacy's Fall Honors Convocation on Oct. 20.
DR. VETRO AIMS TO IMPROVE TREATMENT FOR CANCER PATIENTS
Joseph Vetro, Ph.D., assistant professor of pharmaceutical sciences, wants his research to impact patients. Publication is great, yes. But what does it mean if it doesn't eventually help people? And Dr. Vetro believes that technology to effectively deliver RNA interference molecules (RNAi) can improve treatment for cancer patients. RNAi could be used to suppress gene expression in tumors that causes them to eventually become more resistant to chemotherapy. This could make chemotherapy more effective for people fighting cancer.
UNEMED HONORS DR. ZUCKER AS INNOVATOR OF YEAR
Irving Zucker, Ph.D., landed top honors at UNeMed's annual Research Innovation Awards Ceremony and Reception last week, taking home the 2016 Innovator of the Year Award. Collaborators Joyce Solheim, Ph.D., and Tatiana Bronich, Ph.D., also earned special recognition as the inventors of the "Most Promising New Invention" of 2016. Together, Drs. Solheim and Bronich developed a nanoparticle formulation of a protein called CCL21. The nanoformulated CCL21 has shown great potential for the treatment of cancer.
SPINOFF COMPANY MAY AID RESEARCH EFFORTS
When it comes to cancer, it isn't the primary tumor that gets you, but the metastasis. "We need to do something about metastasis, because that's why people die," said David Oupicky, Ph.D., professor of pharmaceutical sciences and co-director of the Center for Drug Delivery and Nanomedicine.
UNMC HOSTS GATHERING OF CARDIOVASCULAR SCIENTISTS
UNMC will host the inaugural American Journal of Physiology-Heart and Circulatory Editors Scientific Conference on Sept. 8. A world-class international gathering of cardiovascular scientists will present their latest research during the daylong conference in the Sorrell Center. Registration is free and topics will range from stem cell biology to cardiac electrophysiology to vascular biology and everything in-between. The conference will appeal to principal investigators, post-doctoral fellows, graduate students and clinicians interested in the pathogenesis and therapeutics of cardiovascular disease.
Read more ...
NANOMEDICINE THE FOCUS OF NEW COLLABORATION
When the Summer Undergraduate Research Program (SURP) held its poster exhibition on Aug. 11, it was a culmination not only for the longtime program, but for a newer collaboration known as "NanoSURP." As part of the Virginia-Nebraska Alliance, UNMC hosted three students from Hampton University in Hampton, Va., who came to campus specifically to study nanomedicine. The Virginia-Nebraska Alliance is a partnership between UNMC and 11 Virigina area universities. Many are part of the Historically Black Colleges and Universities (HBCU) network.
GOAL: EARLY DETECTION OF PANCREATIC CANCER
The pancreas is located deep within the abdomen, where cancer cells can flourish to a lethal stage without detection. It kills 74 percent of its hosts within the first year of diagnosis and 93 percent within five years. If it has spread to other parts of the body, the average life expectancy dwindles to three to six months. The vast majority of pancreatic cancer cases are diagnosed in late stage because there are no specific tests to detect the disease. Surinder Batra, Ph.D., Stokes-Shackleford Professor and chair of biochemistry and molecular biology, believes he is on the trail for such a marker. It's called micro-RNA.
DR. BATRA TO RECEIVE UNIVERSITY'S ORCA HONOR
Surinder Batra, Ph.D., Stokes-Shackleford Professor and chair of biochemistry and molecular biology, has been award the University of Nebraska's highest honor for research, the Outstanding Research and Creative Activity (ORCA) Award.
TATIANA BRONICH, PH.D., RECOGNIZED FOR CONTRIBUTIONS IN RESEARCH
UNMC scientist Tatiana Bronich, Ph.D., Parke Davis Named Professorship of Pharmaceutical Sciences & co-director of the Center for Drug Delivery and Nanomedicine, College of Pharmacy, was inducted into the elite American Institute for Medical and Biological Engineering's (AIMBE) College of Fellows.
DISTINGUISHED SCIENTIST: LUIS MARKY, PH.D.
This profile is part of a series to highlight the researchers who will be honored at a ceremony for UNMC's 2015 Scientist Laureate, Research Leadership, Distinguished Scientist and New Investigator Award recipients. The Distinguished Scientist Award -- which is sponsored by the chancellor -- recognizes researchers who have been among the most productive scientists in the country during the past five years.
TREATMENT FOR INFLAMMATORY BOWEL DISEASE GOES NANO
The 1.4 million predominantly young adults in the United States affected by inflammatory bowel disease (IBD) need help. The disease, chronic inflammation of the gastrointestinal (GI) tract, is painful, debilitating and comes with an increased risk of colon cancer. David Oupicky, Ph.D., leads an effort to develop a therapeutic strategy for oral treatment of IBD.
DISTINGUISHED SCIENTIST: RAM MAHATO, PH.D.
This profile is part of a series to highlight the researchers who will be honored at a ceremony for UNMC's 2015 Scientist Laureate, Research Leadership, Distinguished Scientist and New Investigator Award recipients.
NEW INVESTIGATOR AWARD: JINGWEI XIE, PH.D.
NEW 'TECH TALK' SERIES BEGINS TUESDAY
The Office of Research will host its first in a new series of "Tech Talks" from 1 to 2 p.m. on Tuesday, Jan. 12, at the Durham Research Center, Room 1006. The inaugural speaker will be Chantey Morris, Ph.D., a research technologist in the College of Pharmacy, who will present "What Can the Nanomaterials Characterization Core Do for You?"
DR. LYUBCHENKO’S REALLY GOOD YEAR
Yuri Lyubchenko, Ph.D., professor of pharmaceutical sciences in the College of Pharmacy, said this quietly, almost with wonder: “It has been a really good year.” It has. Already this year his lab has been awarded a $620,000 grant from the National Science Foundation (NSF) and another from the National Institutes of Health (NIH) for more than $1 million.
EXPERIMENTAL TREATMENT REGIMEN EFFECTIVE AGAINST HIV
Protease inhibitors are a class of antiviral drugs that are commonly used to treat HIV, the virus that causes AIDS. Scientists at UNMC designed a new delivery system for these drugs that, when coupled with a drug developed at the University of Rochester School of Medicine and Dentistry, rid immune cells of HIV and kept the virus in check for long periods.
POSTDOCS RECOGNIZED AT ANNUAL SEMINAR
Jing Li, Ph.D a research associate in the College of Pharmacy, is the 2015 recipient of the UNMC Postdoctoral Pathway to Independence Award.
UNMC RESEARCH TEAM LANDS $8.8 MILLION NIH GRANT
A UNMC research team has been awarded a five-year, $8.8 million grant from the National Institute on Drugs of Abuse-National Institutes of Health for their work on HIV/AIDS treatment and eradication. The goal of the research is to develop a long-acting antiretroviral therapy that could be taken once every six months to provide chemical viral eradication. The work, if realized, could represent a major breakthrough for HIV/AIDS patients, who currently have to take one pill each day.
NCI LAUNCHES NEXT PHASE OF ALLIANCE FOR NANOTECHNOLOGY IN CANCER PROGRAM
The National Cancer Institute (NCI) has again awarded several five-year, multi-institution grants in continued support of its Alliance for Nanotechnology in Cancer program. Given the progress to date of the Alliance, the NCI approved a third phase of the program with a sizable investment in funding. The Alliance program is dedicated to using nanotechnology solutions towards solving cancer biology and oncology problems as well as developing new cancer interventions based on nanotechnology. The program was established in 2004 and funds efforts at academic centers which are engaged in research and translation of new technologies to the clinical environment.
$8 MILLION GRANT RENEWED FOR FOURTH CYCLE
Three cardiovascular researchers at UNMC have received a five-year renewal of a program project grant (PPG) worth more than $8 million to continue their research into chronic heart failure. The renewal marks the fourth cycle of funding for the grant, which comes from the National Heart Lung and Blood Institute at the National Institutes of Health and runs through 2020. When completed, it will bring total funding from the PPG to more than $32 million since its inception in 1999. This is the longest continuously funded PPG at UNMC.
COLLABORATION EYES IMPROVED CANCER DRUG DELIVERY
UNMC and University of North Carolina (UNC) at Chapel Hill nanomedicine researchers received a five-year grant to study whether the properties of certain nanomaterials can improve the delivery of cancer treatments to their tumor targets. The $2.4 million grant from the National Institutes of Health will fund a collaborative research effort between scientists at UNMC and at UNC's Lineberger Comprehensive Cancer Center and the Eshelman School of Pharmacy.
HAMPTON STUDENTS TEAM FOR RESEARCH AT UNMC
A handful of students from historic Hampton University had a memorable past two months at UNMC. They worked with several UNMC researchers and mentors in a prostate cancer research program led by principal investigator Ram Mahato, Ph.D., chair of pharmaceutical sciences in the College of Pharmacy.
Howard Gendelman, M.D., professor and chair of the UNMC Department of Pharmacology and Experimental Neuroscience, received the Humanitarian of the Year Award from the Jewish Federation of...
Mike Boska, Ph.D., whose expertise in magnetic resonance imaging research benefited countless scientists at UNMC, died Saturday (May 13...
In an early phase human clinical trial, researchers at UNMC tested a drug that transforms the immune system for diagnostic and therapeu...